Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 197

1.

Systems change in the context of an initiative to scale up Housing First in Canada.

Nelson G, Worton SK, Macnaughton E, Tsemberis S, MacLeod T, Hasford J, Goering P, Stergiopoulos V, Aubry T, Distasio J.

J Community Psychol. 2019 Jan;47(1):7-20. doi: 10.1002/jcop.22095. Epub 2018 Jun 12.

PMID:
30506925
2.

Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV.

Michel C, Burchert A, Hochhaus A, Saussele S, Neubauer A, Lauseker M, Krause SW, Kolb HJ, Hossfeld DK, Nerl C, Baerlocher GM, Heim D, Brümmendorf TH, Fabarius A, Haferlach C, Schlegelberger B, Balleisen L, Goebeler ME, Hänel M, Ho A, Dengler J, Falge C, Möhle R, Kremers S, Kneba M, Stegelmann F, Köhne CH, Lindemann HW, Waller CF, Spiekermann K, Berdel WE, Müller L, Edinger M, Mayer J, Beelen DW, Bentz M, Link H, Hertenstein B, Fuchs R, Wernli M, Schlegel F, Schlag R, de Wit M, Trümper L, Hebart H, Hahn M, Thomalla J, Scheid C, Schafhausen P, Verbeek W, Eckart MJ, Gassmann W, Schenk M, Brossart P, Wündisch T, Geer T, Bildat S, Schäfer E, Hasford J, Hehlmann R, Pfirrmann M.

Haematologica. 2018 Dec 4. pii: haematol.2018.206797. doi: 10.3324/haematol.2018.206797. [Epub ahead of print]

3.

Blood draws up to 3% of blood volume in clinical trials are safe in children.

Peplow C, Assfalg R, Beyerlein A, Hasford J, Bonifacio E, Ziegler AG.

Acta Paediatr. 2018 Oct 6. doi: 10.1111/apa.14607. [Epub ahead of print]

PMID:
30291644
4.

Navigating Complex Implementation Contexts: Overcoming Barriers and Achieving Outcomes in a National Initiative to Scale Out Housing First in Canada.

Macnaughton E, Nelson G, Worton SK, Tsemberis S, Stergiopoulos V, Aubry T, Hasford J, Distasio J, Goering P.

Am J Community Psychol. 2018 Sep;62(1-2):135-149. doi: 10.1002/ajcp.12268. Epub 2018 Aug 14.

PMID:
30106486
5.

Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV.

Saussele S, Hehlmann R, Fabarius A, Jeromin S, Proetel U, Rinaldetti S, Kohlbrenner K, Einsele H, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Oppliger Leibundgut E, Heim D, Krause SW, Hofmann WK, Hasford J, Pfirrmann M, Müller MC, Hochhaus A, Lauseker M.

Leukemia. 2018 May;32(5):1222-1228. doi: 10.1038/s41375-018-0055-7. Epub 2018 Feb 26.

6.

Efficacy of vildagliptin for prevention of postpartum diabetes in women with a recent history of insulin-requiring gestational diabetes: A phase II, randomized, double-blind, placebo-controlled study.

Hummel S, Beyerlein A, Pfirrmann M, Hofelich A, Much D, Hivner S, Bunk M, Herbst M, Peplow C, Walter M, Kohn D, Hummel N, Kratzsch J, Hummel M, Füchtenbusch M, Hasford J, Ziegler AG; PINGUIN Study Group.

Mol Metab. 2018 Mar;9:168-175. doi: 10.1016/j.molmet.2017.12.015. Epub 2018 Jan 3.

7.

Preventable ADRs leading to hospitalization - results of a long-term prospective safety study with 6,427 ADR cases focusing on elderly patients.

Schmiedl S, Rottenkolber M, Szymanski J, Drewelow B, Siegmund W, Hippius M, Farker K, Guenther IR, Hasford J, Thuermann PA; German Net of Regional Pharmacovigilance Centers (NRPC).

Expert Opin Drug Saf. 2018 Feb;17(2):125-137. doi: 10.1080/14740338.2018.1415322. Epub 2017 Dec 19.

PMID:
29258401
8.

Understanding Systems Change in Early Implementation of Housing First in Canadian Communities: An Examination of Facilitators/Barriers, Training/Technical Assistance, and Points of Leverage.

Worton SK, Hasford J, Macnaughton E, Nelson G, MacLeod T, Tsemberis S, Stergiopoulos V, Goering P, Aubry T, Distasio J, Richter T.

Am J Community Psychol. 2018 Mar;61(1-2):118-130. doi: 10.1002/ajcp.12219. Epub 2017 Dec 18.

PMID:
29251344
9.

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants.

Hehlmann R, Lauseker M, Saußele S, Pfirrmann M, Krause S, Kolb HJ, Neubauer A, Hossfeld DK, Nerl C, Gratwohl A, Baerlocher GM, Heim D, Brümmendorf TH, Fabarius A, Haferlach C, Schlegelberger B, Müller MC, Jeromin S, Proetel U, Kohlbrenner K, Voskanyan A, Rinaldetti S, Seifarth W, Spieß B, Balleisen L, Goebeler MC, Hänel M, Ho A, Dengler J, Falge C, Kanz L, Kremers S, Burchert A, Kneba M, Stegelmann F, Köhne CA, Lindemann HW, Waller CF, Pfreundschuh M, Spiekermann K, Berdel WE, Müller L, Edinger M, Mayer J, Beelen DW, Bentz M, Link H, Hertenstein B, Fuchs R, Wernli M, Schlegel F, Schlag R, de Wit M, Trümper L, Hebart H, Hahn M, Thomalla J, Scheid C, Schafhausen P, Verbeek W, Eckart MJ, Gassmann W, Pezzutto A, Schenk M, Brossart P, Geer T, Bildat S, Schäfer E, Hochhaus A, Hasford J.

Leukemia. 2017 Nov;31(11):2398-2406. doi: 10.1038/leu.2017.253. Epub 2017 Aug 14.

10.

Erratum to: Ethical aspects of clinical trials in rare diseases.

Hasford J, Koch A.

Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2017 Aug;60(8):893. doi: 10.1007/s00103-017-2588-8. No abstract available.

PMID:
28717927
11.

[The impact of the EU Regulation 536/2014 on the tasks and functioning of ethics committees in Germany].

Hasford J.

Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2017 Aug;60(8):830-835. doi: 10.1007/s00103-017-2580-3. Review. German.

PMID:
28638934
12.

Factors influencing adherence in CML and ways to improvement: Results of a patient-driven survey of 2546 patients in 63 countries.

Geissler J, Sharf G, Bombaci F, Daban M, De Jong J, Gavin T, Pelouchova J, Dziwinski E, Hasford J, Hoffmann VS.

J Cancer Res Clin Oncol. 2017 Jul;143(7):1167-1176. doi: 10.1007/s00432-017-2372-z. Epub 2017 Mar 13.

PMID:
28289895
13.

Systematic review and meta-analysis of standard-dose imatinib vs. high-dose imatinib and second generation tyrosine kinase inhibitors for chronic myeloid leukemia.

Hoffmann VS, Hasford J, Deininger M, Cortes J, Baccarani M, Hehlmann R.

J Cancer Res Clin Oncol. 2017 Jul;143(7):1311-1318. doi: 10.1007/s00432-017-2385-7. Epub 2017 Mar 8. Review.

PMID:
28275866
14.

[Ethical aspects of clinical trials in rare diseases].

Hasford J, Koch A.

Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2017 May;60(5):556-562. doi: 10.1007/s00103-017-2537-6. German. Erratum in: Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2017 Jul 17;:.

PMID:
28275835
15.

Smokers with chronic myeloid leukemia are at a higher risk of disease progression and premature death.

Lauseker M, Hasford J, Saussele S, Kremers S, Kraemer D, Lindemann W, Hehlmann R, Pfirrmann M; German CML Study Group.

Cancer. 2017 Jul 1;123(13):2467-2471. doi: 10.1002/cncr.30636. Epub 2017 Feb 13.

16.

No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinib.

Pfirrmann M, Evtimova D, Saussele S, Castagnetti F, Cervantes F, Janssen J, Hoffmann VS, Gugliotta G, Hehlmann R, Hochhaus A, Hasford J, Baccarani M.

J Cancer Res Clin Oncol. 2017 May;143(5):843-850. doi: 10.1007/s00432-016-2321-2. Epub 2017 Jan 12.

PMID:
28083711
17.

Treatment and outcome of 2904 CML patients from the EUTOS population-based registry.

Hoffmann VS, Baccarani M, Hasford J, Castagnetti F, Di Raimondo F, Casado LF, Turkina A, Zackova D, Ossenkoppele G, Zaritskey A, Höglund M, Simonsson B, Indrak K, Sninska Z, Sacha T, Clark R, Bogdanovic A, Hellmann A, Griskevicius L, Schubert-Fritschle G, Sertic D, Guilhot J, Lejniece S, Zupan I, Burgstaller S, Koskenvesa P, Everaus H, Costeas P, Lindoerfer D, Rosti G, Saussele S, Hochhaus A, Hehlmann R.

Leukemia. 2017 Mar;31(3):593-601. doi: 10.1038/leu.2016.246. Epub 2016 Aug 29.

PMID:
27568522
18.

Dominant Cultural Narratives, Racism, and Resistance in the Workplace: A Study of the Experiences of Young Black Canadians.

Hasford J.

Am J Community Psychol. 2016 Mar;57(1-2):158-70. doi: 10.1002/ajcp.12024.

PMID:
27217319
19.

A methodological comparison of two European primary care databases and replication in a US claims database: inhaled long-acting beta-2-agonists and the risk of acute myocardial infarction.

Afonso A, Schmiedl S, Becker C, Tcherny-Lessenot S, Primatesta P, Plana E, Souverein P, Wang Y, Korevaar JC, Hasford J, Reynolds R, de Groot MC, Schlienger R, Klungel O, Rottenkolber M.

Eur J Clin Pharmacol. 2016 Sep;72(9):1105-16. doi: 10.1007/s00228-016-2071-8. Epub 2016 May 24.

PMID:
27216032
20.

Improved survival boosts the prevalence of chronic myeloid leukemia: predictions from a population-based study.

Lauseker M, Gerlach R, Tauscher M, Hasford J.

J Cancer Res Clin Oncol. 2016 Jul;142(7):1441-7. doi: 10.1007/s00432-016-2155-y. Epub 2016 Apr 16.

PMID:
27085527

Supplemental Content

Loading ...
Support Center